Atopic Dermatitis (AD) is a chronic inflammatory disease persisting 
predominantly in the pediatric population. Treatment is generally supervised by 
various medical specialists, including primary care practitioners, allergists, 
and dermatologists. This divergence in disease management allows various 
therapeutic approaches to be administered to patients by supervised physicians. 
This article covers etiology of the disease and summarizes dermatologic 
treatment standards of selected countries binding prior to the registration of 
dupilumab by both the European Medicines Agency (EMA) and Federal Drug 
Administration (FDA) in 2017. Before recent development in targeted therapies 
(small molecules and biologic agents), standards in AD treatment remained 
unchanged for years with extensive similarities across a sample group of 
countries in particular geographic and economic regions. The spectrum of 
available and popular therapeutic options can be categorized into three 
dominating groups: non-pharmacologic, pharmacologic, and systemic interventions. 
Their prescription, in principle, was historically driven by disease severity 
and previous treatment history. However, advances in targeted therapies may 
change AD management guidelines and medical care standards.